Lack of any relationship between ABO and Rh blood groups and clinicopathological features in patients with gastrointestinal stromal tumors: Turkish oncology group

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 8, 2012, Pages 4129-4131

  Urün, Yüksel ^a   Utkan, Güngör ^a   Yalçin, Suayib ^b   Coşkun, Hasan Senol ^c   Koçer, Murat ^d   Ozdemir, Nuriye Yildirim ^e   Kaplan, Mehmet Ali ^f   Arslan, Ulkü Yalçintaş ^g   Ozdemir, Feyyaz ^h   Oztuna, Derya ^a   Akbulut, Hakan ^a   Içli, Fikri ^a  

^a ANKARA UNIVERSITY   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

^c AKDENIZ UNIVERSITY   (Turkey)

^d SULEYMAN DEMIREL UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^e Ankara Numune ^*  (Turkey)

^f DICLE UNIVERSITY   (Turkey)

^g Ankara Oncology Training Hospital   (Turkey)

^h Faculty of Medicine   (Turkey)

Author keywords

ABO blood group; Gastrointestinal stromal tumor; Rh factor; Turkey

Indexed keywords

EID: 84873695059     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.8.4129     Document Type: Article

References (18)

1. Aird I, Bentall HH, Roberts JA (1953). A relationship between cancer of stomach and the abo blood groups. Br Med J, 1, 799-801.
2. Amundadottir L, Kraft P, Stolzenberg-Solomon RZ, et al (2009). Genome-wide association study identifies variants in the abo locus associated with susceptibility to pancreatic cancer. Nat Genet, 41, 986-90.
3. Blanke CD, Rankin C, Demetri GD, et al (2008). Phase iii randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol, 26, 626-32.
4. Casali PG, Blay JY (2010). Gastrointestinal stromal tumours: Esmo clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol, 21, 98-102.
5. Corless CL, Barnett CM, Heinrich MC (2011). Gastrointestinal stromal tumours: Origin and molecular oncology. Nat Rev Cancer, 11, 865-78.
6. Dall'olio F (1996). Protein glycosylation in cancer biology: An overview. Clin Mol Pathol, 49, 126-35.
7. Debiec-Rychter M, Sciot R, Le Cesne A, et al (2006). Kit mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer, 42, 1093-103.
8. Demetri GD, van Oosterom AT, Garrett CR, et al (2006). Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet, 368, 1329-38.
9. Demetri GD, von Mehren M, Blanke CD, et al (2002). Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med, 347, 472-80.
10. Edgren G, Hjalgrim H, Rostgaard K, et al (2010). Risk of gastric cancer and peptic ulcers in relation to abo blood type: a cohort study. Am J Epidemiol, 172, 1280-5.
11. Greer JB, Yazer MH, Raval JS, et al (2010). Significant association between abo blood group and pancreatic cancer. World J Gastroenterol, 16, 5588-91.
12. Heinrich MC, Corless CL, Demetri GD, et al (2003). Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol, 21, 4342-9.
13. Heinrich MC, Owzar K, Corless CL, et al (2008). Correlation of kinase genotype and clinical outcome in the north american intergroup phase iii trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: Calgb 150105 study by cancer and leukemia group b and southwest oncology group. J Clin Oncol, 26, 5360-7.
14. Hirota S, Isozaki K, Moriyama Y, et al (1998). Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science, 279, 577-80.
15. Hosoi E (2008). Biological and clinical aspects of abo blood group system. J Med Invest, 55, 174-82.
16. Iodice S, Maisonneuve P, Botteri E, et al (2010). Abo blood group and cancer. Eur J Cancer, 46, 3345-50.
17. Mazur MT, Clark HB (1983). Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol, 7, 507-19.
18. Wolpin BM, Chan AT, Hartge P, et al (2009). Abo blood group and the risk of pancreatic cancer. J Natl Cancer Inst, 101, 424-31.